[1] Keller, E.E.; Bauer, S.; Roider, K.; Kleindorfer, M.; Törzsök, P.; Tevini, J.; Felder, T.; Aigner, L.; Lusuardi, L. „Montelukast Improves Urinary Bladder Function After Complete Spinal Cord Injury in Rats.” INTERNATION JOURNAL OF MOLECULAR SCIENCES 2025, 26, 5606.
[2] P. Törzsök, F. R. Santer, Y. Kunz, N. C. H. van Creij, P. Tymoszuk, G. Klinglmair, Z. Culig, and R. Pichler, “Biological and therapeutic implications of sex hormone-related gene clustering in testicular cancer,” BASIC AND CLINICAL ANDROLOGY, vol. 35, no. 1, 2025.
[3] P. Törzsök, S. Deininger, L. Lusuardi, M. Abenhardt, D. Oswald, R. Forstner, M. Meissnitzer, C. Deininger, S. Hecht, and H. Brandtner, “MRI in the diagnosis of indeterminate testicular lesions- a game changer?,” EUROPEAN UROLOGY, vol. 85, p. S729, 2024.
[4] S. Deininger, O. Nairz, A. M. Dieplinger, C. Deininger, L. Lusuardi, C. Ramesmayer, J. Peters, D. Oswald, M. Pallauf, S. Bauer, M. C. Brandt, and P. Törzsök, “Real-Time Dosimetry in Endourology: Tracking Staff Radiation Risks,” DIAGNOSTICS, vol. 14, no. 16, 2024.
[5] P. Törzsök, S. Deininger, M. Abenhardt, D. Oswald, L. Lusuardi, C. Deininger, R. Forstner, M. Meissnitzer, H. Brandtner, and S. Hecht, “Discriminating Malignant from Benign Testicular Masses Using Multiparametric Magnetic Resonance Imaging — A Prospective Single-Center Study,” JOURNAL OF CLINICAL MEDICINE, vol. 13, no. 15, 2024.
[6] S. Deininger, A. M. Dieplinger, W. Lauth, L. Lusuardi, P. Törzsök, D. Oswald, M. Pallauf, C. Eiben, J. Peters, E. Erne, Q. Zangl, C. Deininger, and C. Ramesmayer, “Functional Outcome and Safety of Endoscopic Treatment Options for Benign Prostatic Obstruction (BPO) in Patients ≥ 75 Years of Age,” JOURNAL OF CLINICAL MEDICINE, vol. 13, no. 6, 2024.
[7] G. Belge, C. Dumlupinar, T. Nestler, M. Klemke, P. Toerzsoek, E. Trenti, R. Pichler, W. Loidl, Y. Che, A. Hiester, C. Matthies, M. Pichler, P. Paffenholz, L. Kluth, M. Wenzel, J. Sommer, J. Heinzelbecker, P. Schriefer, A. Winter, F. Zengerling, M. W. Kramer, M. Lengert, J. Frey, A. Heidenreich, C. Wuelfing, A. Radtke, and K.-P. Dieckmann, “Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study,” CLINICAL CANCER RESEARCH, vol. 30, no. 2, pp. 404–412, 2024.
[8] P. Törzsök, D. Oswald, C. Steiner, M. Abenhardt, C. Ramesmayer, L. Milinovic, B. Plank, Z. Tischleritsch, L. Lusuardi, and S. Deininger, “Effects of COVID-19 Infection on Spermatogenesis, Oxidative Stress and Erectile Function,” JOURNAL OF CLINICAL MEDICINE, vol. 12, no. 22, p. 7099, 2023.
[9] S. Deininger, P. Törzsök, L. Lusuardi, S. H. M. Deininger, T. Freude, F. Wichlas, and C. Deininger, “Renal Arteriovenous (AV) Fistula after High-Grade Blunt Renal Trauma Caused by Traffic Accidents,” JOURNAL OF CLINICAL MEDICINE, vol. 12, no. 19, p. 6362, 2023.
[10] P. Törzsök, J. Van Goubergen, M. Pichler, R. Pichler, and F. R. Santer, “Isochromosome 12p Formation Regulates Vitamin D Metabolism in Testicular Cancer,” NUTRIENTS, vol. 15, no. 10, 2023.
[11] S. Deininger, T. Gründler, S. H. M. Deininger, K. Lütcke, H. Lütcke, J. Agbesi, W. Ladzaka, E. Gyamfi, F. Wichlas, V. Hofmann, E. Erne, P. Törzsök, L. Lusuardi, J. M. Kern, and C. Deininger, “The Antimicrobial Resistance (AMR) Rates of Uropathogens in a Rural Western African Area—A Retrospective Single-Center Study from Kpando, Ghana,” ANTIBIOTICS, vol. 11, no. 12, p. 1808, 2022.
[12] P. Törzsök, C. Steiner, M. Pallauf, M. Abenhardt, L. Milinovic, B. Plank, A. Rückl, M. Sieberer, L. Lusuardi, and S. Deininger, “Long-Term Follow-Up after Testicular Torsion: Prospective Evaluation of Endocrine and Exocrine Testicular Function, Fertility, Oxidative Stress and Erectile Function,” JOURNAL OF CLINICAL MEDICINE, vol. 11, no. 21, p. 6507, 2022.
[13] D. Oswald, M. Pallauf, S. Deininger, P. Törzsök, M. Sieberer, and C. Eiben, “Neoadjuvant Chemotherapy before Nephroureterectomy in High-Risk Upper Tract Urothelial Cancer: A Systematic Review and Meta-Analysis,” CANCERS, vol. 14, no. 19, p. 4841, 2022.
[14] S. Deininger, L. Lusuardi, M. Pallauf, S. Hecht, R. Forstner, M. Meissnitzer, F. A. Distler, E. Erne, S. Graf, S. Lenart, J. Putz, C. Deininger, and P. Törzsök, “The Diagnostic Value of the Added MR Imaging of the Scrotum in the Preoperative Workup of Sonographically Indeterminate Testicular Lesions—A Retrospective Multicenter Analysis,” CANCERS, vol. 14, no. 15, p. 3594, 2022.
[15] K.-P. Dieckmann, T. Pokrivcak, L. Geczi, D. Niehaus, I. Dralle-Filiz, C. Matthies, T. Dienes, S. Zschäbitz, P. Paffenholz, T. Gschliesser, R. Pichler, M. Mego, P. Bader, F. Zengerling, J. Heinzelbecker, P. Krausewitz, S. Krege, G. Aurilio, C. Aksoy, M. Hentrich, C. Seidel, P. Törzsök, T. Nestler, M. Majewski, A. Hiester, T. Buchler, S. Vallet, H. Studentova, S. Schönburg, D. Niedersüß-Beke, J. Ring, E. Trenti, A. Heidenreich, C. Wülfing, H. Isbarn, U. Pichlmeier, and M. Pichler, “Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1,” THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, vol. 14, 2022.
[16] S. Deininger, P. Toerzsoek, M. Mitterberger, M. Pallauf, D. Oswald, C. Deininger, and L. Lusuardi, “From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guerin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC),” CANCERS, vol. 14, no. 3, 2022.
[17] S. Deininger, P. Torzsok, D. Oswald, and L. Lusuardi, “Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin,” CANCERS, vol. 13, no. 13, 2021.
[18] M. Pallauf, M. C. Hempel, M. C. Hupe, M. May, M. Haccius, D. Weckermann, S. Lebentrau, B. Hoschke, U. Necknig, J. Pfitzenmaier, L. Manka, P. Nuhn, P. Torzsok, L. Lusuardi, and A. S. Merseburger, “Adherence to the EAU Guideline Recommendations for Local Tumor Treatment in Penile Cancer: Results of the European PROspective Penile Cancer Study Group Survey (E-PROPS),” ADVANCES IN THERAPY, vol. 37, no. 12, pp. 4969–4980, 2020.
[19] I. Kocsmar, P. Riesz, B. Gyöngyösi, P. Törzsök, E. Kocsmar, G. Pajor, T. Beöthe, N. Süle, P. Nyirady, Z. Schaff, A. Kiss, and G. Lotz, “Degree of chromosomal abnormalities (UVyScore) detected by UroVysion test from urine-voided bladder cancer cells is able to predict muscle invasion of bladder cancer.” 2018.
[20] G. Lotz, P. Riesz, P. Törzsök, G. Pajor, E. Szekely, J. Kulka, E. Kocsmar, T. Beöthe, I. Kenessey, Z. Schaff, and A. Kiss, “HER2 overexpression in urinary bladder cancer and its relationship to gene amplification and tumour cell polysomy,” VIRCHOWS ARCHIV, vol. 467, no. Suppl. 1, pp. S264–S264, 2015.
[21] G. Lotz, P. Riesz, P. Törzsök, M. Varga, B. Gyöngyösi, G. Pajor, E. Székely, J. Kulka, B. Barkaszi, É. Kocsmár, T. Beöthe, I. Kenessey, A. Majoros, A. Szendrői, P. Nyírády, Z. Schaff, and A. Kiss, “HER2 Overexpressioninurinarybladdercancer and itsrelationshiptogeneamplification and tumor cellpolysomy.” 2014.
[22] A. Holczbauer, B. Gyongyosi, G. Lotz, P. Torzsok, P. Kaposi-Novak, A. Szijarto, P. Tatrai, P. Kupcsulik, Z. Schaff, and A. Kiss, “Increased Expression of Claudin-1 and Claudin-7 in Liver Cirrhosis and Hepatocellular Carcinoma,” PATHOLOGY AND ONCOLOGY RESEARCH, vol. 20, no. 3, pp. 493–502, 2014.
[23] A. Somoracz, A. Korompay, P. Torzsok, A. Patonai, B. Erdelyi-Belle, G. Lotz, Z. Schaff, and A. Kiss, “Tricellulin Expression and its Prognostic Significance in Primary Liver Carcinomas.,” PATHOLOGY AND ONCOLOGY RESEARCH, vol. 20, no. 4, pp. 755–764, 2014.
[24] J. Vargha, P. Riesz, P. Törzsök, M. Varga, B. Gyöngyössy, G. Pajor, E. Székely, J. Kulka, T. Beöthe, I. Kenessey, P. Nyirády, A. Kiss, Z. Schaff, and G. Lotz, “C107 HER2 overexpression in urinary bladder cancer and its relationship to gene amplification and tumor cell polysomy,” EUROPEAN UROLOGY SUPPLEMENTS, vol. 12, no. 4, p. e1215, C107a–e1215, C107b, 2013.
[25] A. Patonai, B. Erdélyi-Belle, A. Korompay, Á. Somorácz, P. Törzsök, I. Kovalszky, T. Barbai, E. Rásó, G. Lotz, Z. Schaff, and A. Kiss, “Molecular Characteristics of Fibrolamellar Hepatocellular Carcinoma,” PATHOLOGY AND ONCOLOGY RESEARCH, vol. 19, no. 1, pp. 63–70, 2013.
[26] A. Somoracz, A. Korompay, P. Toerzsoek, A. Patonai, B. Erdelyi-Belle, G. Lotz, Z. Schaff, and A. Kiss, “TRICELLULIN EXPRESSION CORRELATES WITH OVERALL SURVIVAL IN HEPATOCELLULAR AND CHOLANGIOCELLULAR CARCINOMAS,” JOURNAL OF HEPATOLOGY, vol. 56, no. Suppl. 2, pp. S295–S295, 2012.
[27] P. Törzsök, “Húgyhólyagdaganatok új diagnosztikus és prognosztikus markerei,” 2012.
[28] A. Korompay, K. Borka, G. Lotz, Á. Somorácz, P. Törzsök, B. Erdélyi-Belle, I. Kenessey, Z. Baranyai, F. Zsoldos, P. Kupcsulik, G. Bodoky, Z. Schaff, and A. Kiss, “Tricellulin expression in normal and neoplastic human pancreas,” HISTOPATHOLOGY, vol. 60, no. 6B, pp. E76–E86, 2012.
[29] A. Somoracz, A. Korompay, A. Patonai, B. Erdelyi-Belle, P. Toerzsoek, G. Lotz, Z. Schaff, and A. Kiss, “EXPRESSION OF TRICELLULIN, A RECENTLY IDENTIFIED TIGHT JUNCTION PROTEIN IN NORMAL LIVER AND IN PRIMARY LIVER CANCERS,” JOURNAL OF HEPATOLOGY, vol. 54, no. Suppl. 1, pp. S103–S103, 2011.
[30] P. Toerzsoek, P. Riesz, I. Kenessey, E. Szekely, A. Somoracz, P. Nyirady, I. Romics, Z. Schaff, G. Lotz, and A. Kiss, “Claudins and Ki-67-Potential Markers to Differentiate Low and High Grade Transitional Cell Carcinomas of the Urinary Bladder,” EUROPEAN JOURNAL OF CANCER, vol. 47, no. Suppl. 1, pp. S509–S510, 2011.
[31] A. Korompay, K. Borka, G. Lotz, A. Somoracz, P. Toerzsoek, I. Kenessey, Z. Baranyai, Z. Schaff, and A. Kiss, “Tricellulin Expression in Normal and Tumorous Human Pancreas,” EUROPEAN JOURNAL OF CANCER, vol. 47, no. Suppl. 1, pp. S444–S444, 2011.
[32] P. Törzsök, E. Székely, P. Riesz, A. Korompay, T. Székely, G. Lotz, I. Romics, J. Tímár, Z. Schaff, and A. Kiss, “Expression of Claudins and Their Prognostic Significance in Non-invasive Urothelial Neoplasms of the Human Urinary Bladder,” EUROPEAN JOURNAL OF CANCER, vol. 47, no. Suppl. 1, pp. S510–S510, 2011.
[33] P. Törzsök, P. Riesz, I. Kenessey, E. Székely, Á. Somorácz, P. Nyirády, I. Romics, Z. Schaff, G. Lotz, and A. Kiss, “Claudins and ki-67: potential markers to differentiate low- and high-grade transitional cell carcinomas of the urinary bladder,” JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, vol. 59, no. 11, pp. 1022–1030, 2011.
[34] E. Székely, P. Törzsök, P. Riesz, A. Korompay, A. Fintha, T. Székely, G. Lotz, P. Nyírády, I. Romics, J. Tímár, Z. Schaff, and A. Kiss, “Expression of claudins and their prognostic significance in non-invasive urothelial neoplasms of the human urinary bladder,” JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, vol. 59, no. 10, pp. 932–941, 2011.
[35] G. Zádori, F. Gelley, P. Törzsök, E. Sárváry, A. Doros, A. Deák, P. Nagy, Z. Schaff, A. Kiss, and B. Nemes, “Examination of claudin-1 expression in patients undergoing liver transplantation owing to hepatitis C virus cirrhosis,” TRANSPLANTATION PROCEEDINGS, vol. 43, no. 4, pp. 1267–1271, 2011.
[36] P. Törzsök, E. Székely, A. Korompay, T. Székely, P. Riesz, A. Majoros, A. Szendrői, P. Nyirády, I. Romics, J. Timár, and Z. Schaff, “Claudin expresszió a humán húgyhólyag nem invazív daganataiban,” MAGYAR UROLÓGIA, vol. 22, no. 3, pp. 159–159, 2010.
[37] P. Riesz, E. Székely, P. Törzsök, A. Majoros, A. Szendroi, P. Dombovári, and I. Romics, “Jóindulatú daganat-e a húgyhólyag invertált papillomája?,” ORVOSI HETILAP, vol. 151, no. 3, pp. 92–95, 2010.
[38] P. Riesz, A. Majoros, A. Szendrői, P. Dombóvári, E. Székely, P. Törzsök, and I. Romics, “Jóindulatú daganat-e a húgyhólyag invertált papilloma?,” MAGYAR UROLÓGIA, vol. 21, no. 3, pp. 149–149, 2009.
[39] P. Törzsök, G. Lotz, P. Riesz, E. Székely, Á. Somorácz, I. Romics, Z. Schaff, and A. Kiss, “Claudinok: a humán húgyhólyag low- és high-grade átmeneti sejtes karcinómái elkülönítésének potenciális markerei,” MAGYAR ONKOLÓGIA, vol. 53, no. 5, pp. 133–133, 2009.
[40] Á. Somorácz, Á. Holzbauer, G. Lotz, P. Törzsök, A. Szijártó, P. Kupcsulik, Z. Schaff, and A. Kiss, “A magas claudin-1,-3,-4, és -7 expresszió elkülöníti a colorectalis rákok májáttéteit a primer hepatocellularis carcinomától,” MAGYAR ONKOLÓGIA, vol. 53, no. 5, pp. 116–116, 2009.
[41] P. Riesz, A. Kiss, C. Páska, P. Törzsök, G. Lotz, A. Majoros, M. Szűcs, P. Nyírády, Z. Schaff, and I. Romics, “Claudinok vizsgálata a normál és a malignus húgyhólyagon,” ORVOSTOVÁBBKÉPZŐ SZEMLE, vol. 15, no. Novemberi különszám, p. 6, 2008.
[42] P. Riesz, A. Kiss, P. Törzsök, C. Páska, G. Lotz, A. Majoros, A. Szendrői, Z. Schaff, and I. Romics, “Altered claudin expression in human urinary bladder carcinoma?,” EUROPEAN UROLOGY MEETINGS, vol. 2, no. 7, 2007.
[43] R. P, K. A, T. P, P. C, L. G, M. A, S. A, S. Zs, and R. I, “Altered claudin expression in human urinary bladder carcinogenesis,” EUROPEAN UROLOGY MEETINGS, vol. 2, no. 7, p. 9, 2007.
[44] P. Riesz, A. Kiss, C. Páska, P. Törzsök, G. Lotz, A. Majoros, Z. Schaff, and I. Romics, “A claudinok szerepének vizsgálata húgyhólyagrákban,” MAGYAR ONKOLÓGIA, vol. 51, no. 4, pp. 387–387, 2007.
[45] P. Riesz, P. Nyirády, M. Szűcs, A. Szendrői, A. Majoros, G. Bánfi, A. Kiss, G. Lotz, P. Törzsök, Z. Kelemen, and I. Romics, “Hímvessző-daganatos betegek kezelésével szerzett tapasztalataink,” ORVOSI HETILAP, vol. 148, no. 37, pp. 1751–1756, 2007.
[46] P. Riesz, G. Lotz, C. Páska, A. Szendrői, A. Majoros, Z. Németh, P. Törzsök, T. Szarvas, I. Kovalszky, Z. Schaff, I. Romics, and A. Kiss, “Detection of bladder cancer from the urine using fluorescence in situ hybridization technique,” PATHOLOGY AND ONCOLOGY RESEARCH, vol. 13, no. 3, pp. 187–194, 2007.
[47] A. Kiss, P. Törzsök, C. Páska, G. Lotz, P. Riesz, I. Romics, and Z. Schaff, “Altered claudin expression in human urinary bladder carcinogenesis,” MODERN PATHOLOGY, vol. 19, no. Suppl. 3, pp. 139–139, 2006.